FOXO3 and breast cancer: FOXO3a activity is likely to be deregulated in both the invasive ductal breast carcinoma associated with poor survival, as well as the anthracyclin-resistant breast cancer cell lines as in both cell-types nuclear-localized FOXO3a failed to elicit its anti-proliferative effects.